Real‐World Health Care Resource Utilization and Costs Associated With First‐Line Dronedarone Versus First‐Line Ablation in Adults With Atrial Fibrillation
Over 24-months' follow-up in patients with AF, first-line dronedarone was associated with comparable rates of inpatient/outpatient visits, and lower total payer costs compared with an ablation-based approach.
Authors
- Stephen John Greene (ORCID: https://orcid.org/0000-0001-6912-7374)
- Reno C. Leeming (ORCID: https://orcid.org/0000-0002-5905-0489)
- Shaum Kabadi (ORCID: https://orcid.org/0000-0002-9945-6491)
- Ron Preblick (ORCID: https://orcid.org/0000-0002-7923-041X)
- Samantha Schilsky
- Jason Rashkin
- David S. McKindley (ORCID: https://orcid.org/0000-0002-4402-6814)
- Renee M. Sajedian
- Andrea Russo (ORCID: https://orcid.org/0000-0003-2475-0925)
- Andrew W. Roberts (ORCID: https://orcid.org/0000-0003-3847-8256)
Institutions
- Duke University (US)
- Morristown Medical Center (US)
- Clinical Research Institute (US)
- Cooper Medical School of Rowan University (US)
- Aetion (United States) (US)
- Sanofi (United States) (US)
- C3I (United States) (US)
- Engineering Information Foundation (US)
Publication Details
- Journal
- Clinical Cardiology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1002/clc.70145
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi